MedPath

Litramine in Weight Maintenance

Phase 4
Completed
Conditions
Overweight
Weight Maintenance
Obese
Interventions
Dietary Supplement: Litramine
Dietary Supplement: Placebo
Registration Number
NCT01505387
Lead Sponsor
InQpharm Group
Brief Summary

The effect of Litramine on weight loss has previously been studied during a 12-week intervention period with promising results. The present study looks into the effect of weight maintenance using Litramine following initial weight loss, for a longer period of 24 weeks.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Documented weight loss, achieved over the last 3 to 6 months either from participation in weight loss clinical trials or weight loss regimens, of at least 3% at the point of screening
  • BMI 25-35 before initial weight loss
  • Documented compliance (according to the investigator's judgement) to previous weight loss clinical trials/ regimens
Exclusion Criteria
  • Known sensitivity to the ingredients of the device (citric acid, acacia or Fabaceae family)
  • BMI < 18.5
  • Presence of other factor(s) that, in the investigator's judgement, should preclude subject participation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
LitramineLitramineFibre complex of plant origin n tablet form 2 tablets 3 times daily (oral consumption, after meal)
PlaceboPlaceboIdentical to Litramine 2 tablets 3 times daily (oral consumption, after meal)
Primary Outcome Measures
NameTimeMethod
Mean Change in Body Weight From Baseline to End of 24 Weeks24 weeks

Change in body weight at the end of 24 weeks measured in kg using a calibrated scale. (positive values signify weight gain, while negative values signify weight reduction

Secondary Outcome Measures
NameTimeMethod
Blood Pressure24 weeks

Measured in mm Hg

Full Blood Count24 weeks

Erythrocytes, leukocytes, thrombocytes, haematocrit, haemoglobin, Mean corpuscular volume (MCV), Mean corpuscular haemaglobin (MCH)

Waist and Hip Circumference (cm)24 weeks

Changes from baseline to end of study

Body Mass Index (kg/m^2)24 weeks

Changes from baseline to end of study

Trial Locations

Locations (1)

Barbara Grube

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath